Trastuzumab deruxtecan (Enhertu) demonstrated clinically meaningful benefit and a favorable safety profile at the lower of 2 dose levels in patients with HER2-mutated non–small cell lung cancer (NSCLC), according to interim results of the DESTINY-Lung02 trial (NCT04644237) presented at the 2022 European Society for Medical Oncology (ESMO) Congress.1
The blinded, non-comparative phase 2 trial assessed trastuzumab deruxtecan at 5.4 mg/kg and 6.4 mg/kg every 3 weeks, randomly assigning patients 2:1 to receive the lower dose versus the higher dose. The confirmed overall response rate (cORR) in the prespecified early cohort (PEC) of the study was 53.8% (95% CI, 39.5%-67.8%) at the lower dose level and 42.9% (95% CI, 24.5%-62.8%) at the higher dose level. The lower dose also showed superior safety and tolerability, including a lower rate of interstitial lung disease (ILD).
“The safety profile was generally consistent with the established safety profile of trastuzumab deruxtecan, [but] the patients in the 5.4 mg/kg arm experienced a lower frequency of grade 3 or more drug-related AEs [adverse events] and experienced lower drug discontinuation, dose reduction, and drug interruption,” stated Koichi Goto, MD, in his presentation at the 2022 ESMO Congress. Read more.